Ed Sitar Email & Phone Number

Mahwah, NJ, US

Madison, New Jersey, US

Timber Pharmaceuticals is building an orphan dermatology organization that focuses on mitigating the cost, risk, and time of drug development by leveraging the Orphan Drug pathway for conditions with no FDA Approved treatments. The company’s investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and.

Framingham, Massachusetts, US

Variantyx is a technology-driven precision medicine company providing disruptive solutions to the genetic disorders, reproductive health, and precision oncology markets. Variantyx's whole genome analysis platform allows a better understanding of a person's genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment.

• 9 Meters Biopharma is the new company formed from the merger of Innovate Biopharmaceuticals and RDD Pharma and NAIA Rare Diseases. I was the leader in that strategic transaction. Since the merger I was instrumental in:
• Raising over $100 million of new capital;
• Increasing institutional ownership in the shareholder base from 9% to more than 50%;
• Increasing the market capitalization to allow us to join the Russell 2000;
• Lead investor relations outreach with my deep relationships on the buy side and Wall Street;
• Obtained coverage from eight (8) analysts and improving our financial profile so we are now served by "household name" Investment Banks.

Ramsey, NJ, US

Worked with Series C healthcare technology company in business model rationalization and acquisition integration

Linden, New Jersey, US

• Ammon Labs is a leader in specialty testing for the drug treatment community. As a result of my efforts the value of the Company tripled. Significant accomplishments included:
• Revenue increased 70% while specimen counts were flat;
• Securing national and regional payer contracts
• Implementing financial procedures (where none existed) and upgraded HR including implementing a budget/F,P&A function and establishing internal recruiting function
• Accessing more than $6 million of financing to support the Company’s growth
• Improved risk management function to obtain coverage for areas previously neglected

Cherry Hill, NJ, US

• Cancer Genetics, Inc. is an emerging personalized medicine company with unique diagnostic technology that can help providers deliver precise treatments to patients with difficult to treat blood borne and urogenital.
• Led three acquisitions that quadrupled the size of the Company
• Reorganized the third party billing and reimbursement functions to significantly improve long term reimbursement results
• Refinanced the Company’s debt releasing onerous collateral requirements

Healthagen acquires, builds and supports new businesses that have unique technologies or capabilities that will transform healthcare. I am the financial executive responsible for leading the businesses out of the concept state to commercialization. My broad skills in finance, legal, intellectual property, operations and regulatory contribute to the success.

New York, NY, US

ActiveHealth, a subsidiary of Aetna,is the market leader in clinical decision support systems. AHM's technology supports the transformation of current payer systems to ACO and PCMH models. As CFO I support the transformation of our customer businesses with responsibility for deal pricing in addition to accounting and other finance functions. During my.

Lead US executive for venture backed high technology company. Recapitalized Company from Israel to Delaware. Developed and implemented tax plan to minimize US and international burden. Led fundraising for more than $120 million of financing that introduced new lead investors and lending sources. Lead legal and regulatory function and intimately involved in.

Executive responsible for the financial affairs of a $600 million decentralized pharmacy benefit management, specialty pharmacy and e-commerce/fulfillment company. Key participant in all major decisions. Developed strategy for future development of business. Evaluated and negotiated with acquisition and merger candidates. Successfully negotiated Company’s.

Executive responsible for the financial affairs and business systems of a $140 million dollar publicly traded manufacturer and distributor of disposable medical products. Led re-engineering studies and implementation of changes of both the executive management and MIS areas of the company. Key team member in evaluation of acquisition and joint venture.

Directed the financial affairs of a $500 million multisource pharmaceutical manufacturer and distributor. Responsible for accounting, tax, management information systems, inventory control, budgeting and forecasting. Managed a staff of thirty-five professionals. Interfaced directly with chief executive officer and chairman of the board of directors..

Led audits of various size organizations in the Healthcare, Consumer Product and Education industries

Bachelor Of Science, Accounting

High School Diploma, College Preparation

Grammer School, General Studies